Affymax (OTCMKTS: AFFY) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Affymax and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affymax N/A N/A N/A
Soligenix -86.15% -129.88% -74.33%

Valuation & Earnings

This table compares Affymax and Soligenix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Affymax $41,999.00 42.62 -$47.65 million N/A N/A
Soligenix $6.98 million 1.84 -$6.76 million ($1.36) -1.65

Soligenix has higher revenue and earnings than Affymax.

Volatility & Risk

Affymax has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.

Insider & Institutional Ownership

2.0% of Soligenix shares are held by institutional investors. 1.6% of Affymax shares are held by insiders. Comparatively, 5.0% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Affymax and Soligenix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affymax 0 0 0 0 N/A
Soligenix 0 0 2 0 3.00

Soligenix has a consensus target price of $8.00, suggesting a potential upside of 255.56%. Given Soligenix’s higher possible upside, analysts clearly believe Soligenix is more favorable than Affymax.

Summary

Soligenix beats Affymax on 7 of the 11 factors compared between the two stocks.

Affymax Company Profile

Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Ratings for Affymax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.